1. Clinical & Scientific Overview
Gemcitabine Hydrochloride (TIP-MED-000554, Reference Code [ONC-05]) is classified under
Oncology & Antineoplastic Medicines as a Antimetabolite (Pyrimidine Analogue) • Deoxycytidine Fluorinated Nucleoside Analogue Antimetabolite.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Gemcite (Eli Lilly / Lupin), Gemzar Reference, Cytogem (Dr. Reddy's Laboratories)
Lyophilised Powder for IV Infusion: 200 mg vial, 1,000 mg (1 g) vial
Oncology Specialisation & Cytotoxic Safety Protocol
Antimetabolite (Pyrimidine Analogue)
Antineoplastic Cytotoxic
Standard Regimen & Cycle Context: 1,000–1,250 mg/m2 IV over 30 minutes on Days 1 and 8 (or Days 1, 8, and 15) of a 21- or 28-day cycle.
Signature Dose-Limiting Toxicities & Organ Monitoring: CRITICAL INFUSION RATE TOXICITY: Prolonging infusion beyond 60 minutes saturates deoxycytidine kinase and drastically increases intracellular dFdCTP accumulation in myeloid progenitors, causing severe myelosuppression; other toxicities include transient 'Gemcitabine flu' (fever, myalgia), capillary leak syndrome, and thrombotic microangiopathy (HUS).
Extravasation, Premedication & Safe Cytotoxic Handling: Infuse strictly over 30 minutes (never >60 minutes unless following a specialized fixed-dose-rate protocol); acts as a potent radiosensitiser (avoid concurrent thoracic radiotherapy due to severe oesophagitis/pneumonitis).
3. Mechanism of Action & Pharmacodynamics
Prodrug phosphorylated by deoxycytidine kinase to gemcitabine diphosphate (dFdCDP, which inhibits ribonucleotide reductase, depleting normal dCTP pools and self-potentiating its own uptake) and gemcitabine triphosphate (dFdCTP, which incorporates into DNA and causes 'masked chain termination').
4. Therapeutic Indications & Evidence-Supported Uses
- Pancreatic adenocarcinoma
- Locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), Urothelial bladder cancer, Ovarian and Breast carcinoma
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): 1,000–1,250 mg/m2 IV over 30 minutes on Days 1 and 8 (or Days 1, 8, and 15) of a 21- or 28-day cycle.
Administration & Meal Timing: 1,000–1,250 mg/m2 IV over 30 minutes on Days 1 and 8 (or Days 1, 8, and 15) of a 21- or 28-day cycle.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Gemcitabine or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: CRITICAL INFUSION RATE TOXICITY: Prolonging infusion beyond 60 minutes saturates deoxycytidine kinase and drastically increases intracellular dFdCTP accumulation in myeloid progenitors, causing severe myelosuppression; other toxicities include transient 'Gemcitabine flu' (fever, myalgia), capillary leak syndrome, and thrombotic microangiopathy (HUS).
8. Adverse Effects Profile
- CRITICAL INFUSION RATE TOXICITY: Prolonging infusion beyond 60 minutes saturates deoxycytidine kinase and drastically increases intracellular dFdCTP accumulation in myeloid progenitors, causing severe myelosuppression; other toxicities include transient 'Gemcitabine flu' (fever, myalgia), capillary leak syndrome, and thrombotic microangiopathy (HUS).
- CRITICAL INFUSION RATE TOXICITY: Prolonging infusion beyond 60 minutes saturates deoxycytidine kinase and drastically increases intracellular dFdCTP accumulation in myeloid progenitors, causing severe myelosuppression; other toxicities include transient 'Gemcitabine flu' (fever, myalgia), capillary leak syndrome, and thrombotic microangiopathy (HUS).
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CRITICAL INFUSION RATE TOXICITY: Prolonging infusion beyond 60 minutes saturates deoxycytidine kinase and drastically increases intracellular dFdCTP accumulation in myeloid progenitors, causing severe myelosuppression; other toxicities include transient 'Gemcitabine flu' (fever, myalgia), capillary leak syndrome, and thrombotic microangiopathy (HUS).
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Infuse strictly over 30 minutes (never >60 minutes unless following a specialized fixed-dose-rate protocol); acts as a potent radiosensitiser (avoid concurrent thoracic radiotherapy due to severe oesophagitis/pneumonitis).
Pharmacist Patient Counselling Points:
- Infuse strictly over 30 minutes (never >60 minutes unless following a specialized fixed-dose-rate protocol); acts as a potent radiosensitiser (avoid concurrent thoracic radiotherapy due to severe oesophagitis/pneumonitis).
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: Infuse strictly over 30 minutes (never >60 minutes unless following a specialized fixed-dose-rate protocol); acts as a potent radiosensitiser (avoid concurrent thoracic radiotherapy due to severe oesophagitis/pneumonitis).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [ONC-04] Cytarabine (Ara-C) — Antimetabolite (S-Phase Specific) • Pyrimidine Nucleoside Analogu
- [ONC-06] Capecitabine — Antimetabolite (Fluoropyrimidine) • Oral Fluoropyrimidine Carbama
- [ONC-07] Pemetrexed Disodium — Antimetabolite (Folate Antagonist) • Multi-Targeted Antifolate An
- [ONC-08] Epirubicin Hydrochloride — Anthracycline Cytotoxic Antibiotic • 4'-Epimer Anthracycline Topo
